Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous thromboembolism after penile cancer surgery: a UK PeCaN study.

BJU international·2026
Same author

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Nature cancer·2026
Same author

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

The Lancet. Oncology·2026
Same author

A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

The Prostate·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Emily Grist1, Peter Dutey-Magni2, Marina A Parry1

  • 1Cancer Institute, University College London, London, UK.

Cell
|August 27, 2025
PubMed
Summary
This summary is machine-generated.

New biomarkers predict prostate cancer survival and response to treatments like docetaxel. These findings could lead to personalized medicine for advanced prostate cancer patients, improving treatment selection and outcomes.

Keywords:
PTENSTAMPEDE trialabirateronedocetaxelprostate cancertranscriptome-wide expression classifiers

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Related Experiment Videos

Last Updated: Sep 10, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Area of Science:

  • Oncology
  • Genomics
  • Translational Research

Background:

  • Advanced prostate cancer treatment relies on hormone therapy, but patient outcomes vary widely.
  • Currently, no predictive tests exist to guide treatment selection for optimal patient benefit.

Purpose of the Study:

  • To identify novel biomarker-treatment pairings for advanced prostate cancer.
  • To examine associations between biological pathways and survival outcomes in patients undergoing phase 3 trials.

Main Methods:

  • Analysis of transcriptome-wide expression signatures and immunohistochemistry markers (Ki-67, PTEN) in 1,523 prostate tumors.
  • Examination of associations between biomarkers and 14-year survival in patients from phase 3 trials of docetaxel or abiraterone.

Main Results:

  • Androgen receptor signaling correlated with longer survival, while increased proliferation predicted shorter survival.
  • The decipher RNA signature predicted survival benefit from docetaxel in metastatic prostate cancer.
  • Transcriptome-based PTEN inactivation classification identified tumors with shorter survival on hormone therapy but sensitivity to docetaxel.

Conclusions:

  • Transcriptome classifiers can predict docetaxel benefit in advanced prostate cancer.
  • Biomarker-driven treatment selection could improve patient management and outcomes.